Sanofi (SNY) Competitors

Novo Nordisk A/S (NYSE:NVO) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

Which has more risk & volatility, NVO or SNY?

Novo Nordisk A/S has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500.

Do analysts recommend NVO or SNY?

Novo Nordisk A/S currently has a consensus price target of $112.00, indicating a potential upside of 62.20%. Sanofi has a consensus price target of $61.50, indicating a potential upside of 25.81%. Given Novo Nordisk A/S's higher probable upside, research analysts clearly believe Novo Nordisk A/S is more favorable than Sanofi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.27
Sanofi	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.11

Which has higher earnings & valuation, NVO or SNY?

Novo Nordisk A/S has higher earnings, but lower revenue than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$42.12B	7.32	$14.64B	$3.38	20.43
Sanofi	$44.46B	2.70	$6.02B	$2.80	17.46

Do institutionals and insiders believe in NVO or SNY?

11.5% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 14.0% of Sanofi shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by company insiders. Comparatively, 1.0% of Sanofi shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Is NVO or SNY a better dividend stock?

Novo Nordisk A/S pays an annual dividend of $1.64 per share and has a dividend yield of 2.4%. Sanofi pays an annual dividend of $1.60 per share and has a dividend yield of 3.3%. Novo Nordisk A/S pays out 48.5% of its earnings in the form of a dividend. Sanofi pays out 57.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Does the media refer more to NVO or SNY?

In the previous week, Novo Nordisk A/S had 10 more articles in the media than Sanofi. MarketBeat recorded 31 mentions for Novo Nordisk A/S and 21 mentions for Sanofi. Novo Nordisk A/S's average media sentiment score of 1.09 beat Sanofi's score of 0.65 indicating that Novo Nordisk A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	25 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Sanofi	6 Very Positive mention(s)	2 Positive mention(s)	11 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Is NVO or SNY more profitable?

Novo Nordisk A/S has a net margin of 34.52% compared to Sanofi's net margin of 14.56%. Novo Nordisk A/S's return on equity of 80.94% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	34.52%	80.94%	24.23%
Sanofi	14.56%	17.15%	9.80%

Summary

Novo Nordisk A/S beats Sanofi on 12 of the 19 factors compared between the two stocks.